Loading…
Back To Schedule
Friday, June 18 • 12:00pm - 1:00pm
#527 OD: Building on Opportunities from a Pandemic to Influence the Future of Clinical Research

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Advanced

Responding and adapting to the changes invoked by the COVID-19 pandemic on clinical research foster new opportunities in many aspects of clinical research. At the heart of these opportunities are the need for statistical and analytical innovation. This session will highlight several areas where statistical and analytical innovation have informed our response to the COVID-19 pandemic and what this means for the future of clinical research. There will be a talk on the use of artificial intelligence for the rapid identification and determination of potential therapeutics that have the best chance of treating against those infected with the SAR-COV-2 virus. Another talk will discuss how the COVID-19 pandemic has magnified the vulnerability and unsustainability of the current clinical development which emphasizes the need to move towards more pragmatic, patient-centric, and adaptive trial designs that make extensive use of computer technology. The final talk will discuss how analytics and data visualization foster an ability to make timely decisions that impact the healthcare sector and clinical development.

Learning Objectives

Describe an artificial intelligence/machine learning approach that can be used to identify candidate treatments; Describe the immediate, and potential long-term, impact of the COVID-19 pandemic on the clinical-research enterprise, both in terms of trials in this disease as well as non-COVID-19 trials; Assess how data and analytics can be used to respond to public health challenges.

Chair

Mat Soukup, PhD

Speaker

Fighting COVID-19 with Trusted Analytics
Mark Lambrecht, PhD

Randomized Controlled Trials (RCTs): Lessons from COVID-19
Marc E. Buyse, DrSc

Industry Update
Sherrine Eid, MPH



Speakers
avatar for Marc Buyse

Marc Buyse

Chief Scientific Officer, IDDI, United States
Marc Buyse holds master’s degrees from Brussels University (Belgium), the Cranfield School of Management (UK) and a doctorate degree from the Harvard School of Public Health (USA). He had worked for 12 years at the EORTC in Brussels and for 2 years at the Dana Farber Cancer Institute... Read More →
avatar for Mat Soukup

Mat Soukup

Deputy Director, Division of Biometrics VII, OB, OTS CDER, FDA, United States
Following his educational endeavors in statistics at the University of Minnesota-Morris and the University of Virginia, Mat joined FDA/CDER in September 2004. His first 6 years were spent reviewing dermatology and dental products before joining the Division of Biometrics 7 as Team... Read More →
ML

Mark Lambrecht

Director, Global Health and Life Sciences Practice, SAS Institute Inc., Belgium
Mark Lambrecht leads a senior team that is responsible for SAS’ global health care and life sciences market strategy. In 2020, he led the COVID-19 Scientific Advisory Team, a response within SAS to help organizations analytically manage the impact of the pandemic. Lambrecht is an... Read More →
avatar for Sherrine Eid

Sherrine Eid

Health and Life Sciences Industry Consultant, SAS, SAS, United States
Eid has more than 20 years of experience in real-world evidence, epidemiology and biostatistics. Her passion for better public health led her to work for USAID, CDC and other donors in global health development with a focus on reproductive health and family planning and infectious... Read More →


Friday June 18, 2021 12:00pm - 1:00pm EDT
TBD Virtual Event Horsham, PA 19044
  11: Statistics, Session |   20: Early Access Content, Session
  • Beginner Intermediate
  • Student Programming Regulator Thinking,COVID-19 - Pandemic,What's Next,Innovative Trial Design
  • Tags Session